{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:18:14Z","timestamp":1784546294150,"version":"3.55.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2023ZD0502400"],"award-info":[{"award-number":["2023ZD0502400"]}]},{"name":"Major Program of the National Natural Science Foundation of China","award":["82293630"],"award-info":[{"award-number":["82293630"]}]},{"name":"Being Nova Program","award":["20220484076"],"award-info":[{"award-number":["20220484076"]}]},{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science & Technology Commission","doi-asserted-by":"crossref","award":["Z211100002921071"],"award-info":[{"award-number":["Z211100002921071"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Peking University Medicine Fund for world's leading discipline or discipline cluster development","award":["71003Y3035"],"award-info":[{"award-number":["71003Y3035"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06738-2","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T01:44:35Z","timestamp":1768959875000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Blinatumomab exposure prior to allogeneic stem cell transplantation is associated with increased Epstein-Barr virus reactivation"],"prefix":"10.1007","volume":"105","author":[{"given":"Hai-Lu","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Fan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian-Ying","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang-Fang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Su","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan-Ping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu-Ying","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"issue":"19","key":"6738_CR1","doi-asserted-by":"publisher","first-page":"5898","DOI":"10.1182\/bloodadvances.2023010539","volume":"7","author":"G Reynolds","year":"2023","unstructured":"Reynolds G, Cliff ERS, Mohyuddin GR, Popat R, Midha S, Liet Hing MN et al (2023) Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis. Blood Adv 7(19):5898\u20135903","journal-title":"Blood Adv"},{"issue":"13","key":"6738_CR2","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1182\/bloodadvances.2024012916","volume":"8","author":"GK Reynolds","year":"2024","unstructured":"Reynolds GK, Maclean M, Cliff ERS, Teh BW, Thursky KA, Slavin MA et al (2024) Infections in patients with lymphoma treated with bispecific antibodies: a systematic review and meta-analysis. Blood Adv 8(13):3555\u20133559","journal-title":"Blood Adv"},{"issue":"14","key":"6738_CR3","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","volume":"131","author":"N Gokbuget","year":"2018","unstructured":"Gokbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C et al (2018) Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood 131(14):1522\u20131531","journal-title":"Blood"},{"key":"6738_CR4","doi-asserted-by":"crossref","unstructured":"Kyriakidis I, Mantadakis E, Stiakaki E, Groll AH, Tragiannidis A (2022) Infectious complications of targeted therapies in children with leukemias and lymphomas. Cancers (Basel) 14(20):5022","DOI":"10.3390\/cancers14205022"},{"issue":"2","key":"6738_CR5","first-page":"217","volume":"30","author":"G Llaurador","year":"2024","unstructured":"Llaurador G, Shaver K, Wu M, Wang T, Gillispie A, Doherty E et al (2024) Blinatumomab therapy is associated with favorable outcomes after allogeneic hematopoietic cell transplantation in pediatric patients with B cell acute lymphoblastic leukemia. Transpl Cell Ther 30(2):217\u2013227","journal-title":"Transpl Cell Ther"},{"issue":"17","key":"6738_CR6","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","volume":"383","author":"R Foa","year":"2020","unstructured":"Foa R, Bassan R, Vitale A, Elia L, Piciocchi A, Puzzolo MC et al (2020) Dasatinib-Blinatumomab for Ph-Positive acute lymphoblastic leukemia in adults. N Engl J Med 383(17):1613\u20131623","journal-title":"N Engl J Med"},{"issue":"7","key":"6738_CR7","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1182\/bloodadvances.2019000874","volume":"4","author":"A Rambaldi","year":"2020","unstructured":"Rambaldi A, Huguet F, Zak P, Cannell P, Tran Q, Franklin J et al (2020) Blinatumomab consolidation and maintenance therapy in adults with relapsed\/refractory B-precursor acute lymphoblastic leukemia. Blood Adv 4(7):1518\u20131525","journal-title":"Blood Adv"},{"issue":"7","key":"6738_CR8","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3324\/haematol.2016.144428","volume":"101","author":"J Styczynski","year":"2016","unstructured":"Styczynski J, van der Velden W, Fox CP, Engelhard D, de la Camara R, Cordonnier C et al (2016) Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines. Haematologica 101(7):803\u2013811","journal-title":"Haematologica"},{"issue":"2","key":"6738_CR9","doi-asserted-by":"publisher","first-page":"135","DOI":"10.5045\/br.2022.2021163","volume":"57","author":"S Wo","year":"2022","unstructured":"Wo S, Levavi H, Mascarenhas J, Kremyanskaya M, Navada S, Bar-Natan M et al (2022) Immunoglobulin repletion during blinatumomab therapy does not reduce the rate of secondary hypogammaglobulinemia and associated infectious risk. Blood Res 57(2):135\u2013143","journal-title":"Blood Res"},{"key":"6738_CR10","doi-asserted-by":"crossref","unstructured":"Cao W, Li N, Wang G, Xu H, Yang Y, Wang J et al (2025) Efficacy and safety comparison of CAR-T and blinatumomab immunotherapy as bridge-to-transplant strategies in relapsed\/refractory B cell acute lymphoblastic leukemia. J Translational Med 23(1):391","DOI":"10.1186\/s12967-025-06399-1"},{"issue":"8","key":"6738_CR11","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1182\/blood-2005-05-2146","volume":"107","author":"DP Lu","year":"2006","unstructured":"Lu DP, Dong L, Wu T, Huang XJ, Zhang MJ, Han W et al (2006) Conditioning including antithymocyte Globulin followed by unmanipulated HLA-mismatched\/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 107(8):3065\u20133073","journal-title":"Blood"},{"issue":"6","key":"6738_CR12","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1182\/blood-2014-03-563130","volume":"124","author":"Y Wang","year":"2014","unstructured":"Wang Y, Chang YJ, Xu LP, Liu KY, Liu DH, Zhang XH et al (2014) Who is the best donor for a related HLA haplotype-mismatched transplant? Blood 124(6):843\u2013850","journal-title":"Blood"},{"key":"6738_CR13","volume-title":"The EBMT handbook: hematopoietic cell transplantation and cellular therapies","year":"2024","unstructured":"Sureda A, Corbacioglu S, Greco R, Kr\u00f6ger N, Carreras E (eds) (2024) The EBMT handbook: hematopoietic cell transplantation and cellular therapies, 8th edn. Springer, Cham (CH)","edition":"8"},{"issue":"12","key":"6738_CR14","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1016\/j.bbmt.2015.07.035","volume":"21","author":"L-P Xu","year":"2015","unstructured":"Xu L-P, Zhang C-L, Mo X-D, Zhang X-H, Chen H, Han W et al (2015) Epstein-Barr Virus\u2013Related Post-Transplantation lymphoproliferative disorder after unmanipulated human leukocyte antigen haploidentical hematopoietic stem cell transplantation: Incidence, risk Factors, Treatment, and clinical outcomes. Biol Blood Marrow Transplant 21(12):2185\u20132191","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"6738_CR15","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1038\/sj.leu.2402890","volume":"17","author":"A Loffler","year":"2003","unstructured":"Loffler A, Gruen M, Wuchter C, Schriever F, Kufer P, Dreier T et al (2003) Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19\/anti-CD3 single-chain antibody construct. Leukemia 17(5):900\u2013909","journal-title":"Leukemia"},{"key":"6738_CR16","doi-asserted-by":"publisher","first-page":"5891","DOI":"10.1126\/science.1158545","volume":"321","author":"R Bargou","year":"2008","unstructured":"Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S et al (2008) Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321:5891","journal-title":"Science"},{"issue":"26","key":"6738_CR17","doi-asserted-by":"publisher","first-page":"4010","DOI":"10.1182\/blood-2014-08-596403","volume":"125","author":"E Jabbour","year":"2015","unstructured":"Jabbour E, O\u2019Brien S, Ravandi F, Kantarjian H (2015) Monoclonal antibodies in acute lymphoblastic leukemia. Blood 125(26):4010\u20134016","journal-title":"Blood"},{"issue":"6","key":"6738_CR18","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.3324\/haematol.2023.283818","volume":"109","author":"KU Lyons","year":"2024","unstructured":"Lyons KU, Gore L (2024) Bispecific T-cell engagers in childhood B-acute lymphoblastic leukemia. Haematologica 109(6):1668\u20131676","journal-title":"Haematologica"},{"issue":"9","key":"6738_CR19","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1001\/jama.2021.0669","volume":"325","author":"PA Brown","year":"2021","unstructured":"Brown PA, Ji L, Xu X, Devidas M, Hogan LE, Borowitz MJ et al (2021) Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on Disease-Free survival in Children, Adolescents, and young adults with first relapse of B-Cell acute lymphoblastic leukemia: A randomized clinical trial. JAMA 325(9):833\u2013842","journal-title":"JAMA"},{"key":"6738_CR20","doi-asserted-by":"crossref","unstructured":"Andreescu M (2023) Risk of infections secondary to the use of targeted therapies in hematological malignancies. Life (Basel) 13(6):1272","DOI":"10.3390\/life13061272"},{"issue":"3","key":"6738_CR21","first-page":"e00035","volume":"33","author":"JS Davis","year":"2020","unstructured":"Davis JS, Ferreira D, Paige E, Gedye C, Boylea M (2020) Infectious complications of biological and small molecule. Clincal Microbiol Reviews 33(3):e00035\u2013e00019","journal-title":"Clincal Microbiol Reviews"},{"key":"6738_CR22","doi-asserted-by":"publisher","first-page":"929122","DOI":"10.3389\/fped.2022.929122","volume":"10","author":"MM Marrapodi","year":"2022","unstructured":"Marrapodi MM, Mascolo A, di Mauro G, Mondillo G, Pota E, Rossi F (2022) The safety of blinatumomab in pediatric patients with acute lymphoblastic leukemia: A systematic review and meta-analysis. Front Pediatr 10:929122","journal-title":"Front Pediatr"},{"key":"6738_CR23","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ejca.2020.12.022","volume":"146","author":"G Martinelli","year":"2021","unstructured":"Martinelli G, Boissel N, Chevallier P, Ottmann O, Gokbuget N, Rambaldi A et al (2021) Long-term follow-up of blinatumomab in patients with relapsed\/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: final analysis of ALCANTARA study. Eur J Cancer 146:107\u2013114","journal-title":"Eur J Cancer"},{"issue":"Suppl 2","key":"6738_CR24","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1016\/j.cmi.2018.02.003","volume":"24","author":"M Mikulska","year":"2018","unstructured":"Mikulska M, Lanini S, Gudiol C, Drgona L, Ippolito G, Fernandez-Ruiz M et al (2018) ESCMID study group for infections in compromised hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52). Clin Microbiol Infect 24(Suppl 2):S71\u2013S82","journal-title":"Clin Microbiol Infect"},{"issue":"8","key":"6738_CR25","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/j.bbmt.2019.04.010","volume":"25","author":"AS Stein","year":"2019","unstructured":"Stein AS, Kantarjian H, Gokbuget N, Bargou R, Litzow MR, Rambaldi A et al (2019) Blinatumomab for acute lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transpl 25(8):1498\u20131504","journal-title":"Biol Blood Marrow Transpl"},{"issue":"10","key":"6738_CR26","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1080\/14740338.2017.1338270","volume":"16","author":"AC Wilke","year":"2017","unstructured":"Wilke AC, Gokbuget N (2017) Clinical applications and safety evaluation of the new CD19 specific T-cell engager antibody construct blinatumomab. Expert Opin Drug Saf 16(10):1191\u20131202","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"6738_CR27","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1080\/16078454.2022.2111992","volume":"27","author":"H Zhou","year":"2022","unstructured":"Zhou H, Yin Q, Jin J, Liu T, Cai Z, Jiang B et al (2022) Efficacy and safety of blinatumomab in Chinese adults with Ph-negative relapsed\/refractory B-cell precursor acute lymphoblastic leukemia: A multicenter open-label single-arm China registrational study. Hematology 27(1):917\u2013927","journal-title":"Hematology"},{"issue":"3","key":"6738_CR28","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s10637-024-01435-1","volume":"42","author":"H Zhou","year":"2024","unstructured":"Zhou H, Wu X, Yang Z, Lu S, Zhang X, Yang X et al (2024) Real-world evidence on treatment pattern, effectiveness, and safety of blinatumomab in Chinese patients with B-cell acute lymphoblastic leukemia. Invest New Drugs 42(3):299\u2013308","journal-title":"Invest New Drugs"},{"issue":"9","key":"6738_CR29","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, Stein A, Gokbuget N, Fielding AK, Schuh AC, Ribera JM et al (2017) Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med 376(9):836\u2013847","journal-title":"N Engl J Med"},{"key":"6738_CR30","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1146\/annurev-immunol-032414-112326","volume":"33","author":"GS Taylor","year":"2015","unstructured":"Taylor GS, Long HM, Brooks JM, Rickinson AB, Hislop AD (2015) The immunology of Epstein-Barr virus-induced disease. Annu Rev Immunol 33:787\u2013821","journal-title":"Annu Rev Immunol"},{"issue":"9","key":"6738_CR31","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1182\/blood.2019000928","volume":"135","author":"SGTS Latour","year":"2020","unstructured":"Latour SGTS (2020) Primary immunodeficiencies reveal the molecular requirements for effective host defense against EBV infection. Blood 135(9):644\u2013655","journal-title":"Blood"},{"issue":"1","key":"6738_CR32","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","volume":"16","author":"MS Topp","year":"2015","unstructured":"Topp MS, Gokbuget N, Stein AS, Zugmaier G, O\u2019Brien S, Bargou RC et al (2015) Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol 16(1):57\u201366","journal-title":"Lancet Oncol"},{"issue":"1","key":"6738_CR33","doi-asserted-by":"publisher","first-page":"e2018029","DOI":"10.4084\/mjhid.2018.029","volume":"10","author":"W So","year":"2018","unstructured":"So W, Pandya S, Quilitz R, Shah B, Greene JN (2018) Infectious risks and complications in adult leukemic patients receiving blinatumomab. Mediterr J Hematol Infect Dis 10(1):e2018029","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"9","key":"6738_CR34","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/bcj.2014.64","volume":"4","author":"G Zugmaier","year":"2014","unstructured":"Zugmaier G, Topp MS, Alekar S, Viardot A, Horst HA, Neumann S et al (2014) Long-term follow-up of serum Immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia. Blood Cancer J 4(9):244","journal-title":"Blood Cancer J"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06738-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06738-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06738-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T07:03:39Z","timestamp":1771398219000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06738-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":34,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["6738"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06738-2","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]},"assertion":[{"value":"8 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"43"}}